Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:alsoKnownAs |
gptkb:brincidofovir
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J05AB16
|
| gptkbp:CASNumber |
444805-28-1
|
| gptkbp:chemicalClass |
lipid conjugate of cidofovir
|
| gptkbp:contraindication |
hypersensitivity to brincidofovir
|
| gptkbp:developedBy |
gptkb:Chimerix
|
| gptkbp:hasMolecularFormula |
C27H52N3O7P
|
| https://www.w3.org/2000/01/rdf-schema#label |
CMX001
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Tembexa
|
| gptkbp:mechanismOfAction |
inhibits viral DNA polymerase
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
elevated liver enzymes
gastrointestinal symptoms |
| gptkbp:usedFor |
treatment of smallpox
treatment of adenovirus infections treatment of cytomegalovirus infections |
| gptkbp:bfsParent |
gptkb:brincidofovir
|
| gptkbp:bfsLayer |
7
|